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Pancreatic cancer is the fifth most common cause of cancer death. Identification of defined patient groups based on a prognostic
index may improve the prediction of survival and selection of therapy. Many prognostic factors have been identified often based on
retrospective, underpowered studies with unclear analyses. Data from 653 patients were analysed. Continuous variables are often
simplified assuming a linear relationship with log hazard or introducing a step function (dichotomising). Misspecification may lead to
inappropriate conclusions but has not been previously investigated in pancreatic cancer studies. Models based on standard
assumptions were compared with a novel approach using nonlinear fractional polynomial (FP) transformations. The model based on
FP-transformed covariates was most appropriate and confirmed five previously reported prognostic factors: albumin, CA19-9, alkaline
phosphatase, LDH and metastases, and identified three additional factors not previously reported: WBC, AST and BUN. The effects
of CA19-9, alkaline phosphatase, AST and BUN may go unrecognised due to simplistic assumptions made in statistical modelling. We
advocate a multivariable approach that uses information contained within continuous variables appropriately. The functional form of
the relationship between continuous covariates and survival should always be assessed. Our model should aid individual patient risk
stratification and the design and analysis of future trials in pancreatic cancer.
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Pancreatic ductal adenocarcinoma is a common cause of cancer
death and is difficult to treat because clinical presentation is often
late, and the disease is resistant to conventional chemotherapy.
Long-term survival remains poor with a 5-year survival rate of
0.4–4% (Bramhall et al, 1995; Jemal et al, 2003). Multivariable
prognostic models are important for grouping patients into risk
sets for predicting survival and treating appropriately. There is
currently no prognostic tool in routine use to identify subgroups of
pancreatic cancer patients for selection and stratification of
treatment and prediction of survival.
Because of its poor prognosis, few prognostic factors may be
expected for patients with advanced pancreatic cancer; however,
many possible factors have been identified. The majority of
prognostic factor studies are questionable in terms of sample size
and statistical methods, most based on small retrospective
analyses. Literature searches (ISI Web of Science and Ovid
Technologies databases) identified 36 prognostic factor studies
reporting a total of 34 possible prognostic factors for advanced
pancreatic cancer patients (Table 1) grouped as surgical, clinical,
laboratory or demographic. Four studies (Johnson et al, 2001;
Berlin et al, 2002; Ducreux et al, 2002; Maisey et al, 2002) were
randomised controlled trials reporting five prognostic factors from
multivariate analyses, namely metastases, tumour site, perfor-
mance status, alkaline phosphatase and treatment. The remaining
32 studies (Friedman and van den Eeden, 1993; Yasue et al, 1994;
Falconer et al, 1995; Lundin et al, 1995; Ishii et al, 1996;
Rothenberg et al, 1996; Shibamoto et al, 1996; Cubiella et al,
1999; Storniolo et al, 1999; Halm et al, 2000; Terwee et al, 2000;
Trigui et al, 2000; Ueno et al, 2000; Ikeda et al, 2001; Ridwelski
et al, 2001; Tas et al, 2001; Tsuruta et al, 2001; Saad et al, 2002;
Bachmann et al, 2003; Engelken et al, 2003; Fujino et al, 2003;
Karayiannakis et al, 2003; Micke et al, 2003; Ohigashi et al, 2003;
Paillaud et al, 2003; Stemmler et al, 2003; Talar-Wojnarowska et al,
2003; Ziske et al, 2003; Gupta et al, 2004; Kuhlmann et al, 2004;
Watanabe et al, 2004; Ni et al, 2005) were based on consecutive
series of patients, often retrospective, often single-centre, of which
15 studies were based on fewer than 100 patients (Yasue et al, 1994;
Ishii et al, 1996; Rothenberg et al, 1996; Halm et al, 2000; Ikeda
et al, 2001; Tsuruta et al, 2001; Saad et al, 2002; Karayiannakis
et al, 2003; Micke et al, 2003; Ohigashi et al, 2003; Paillaud et al,
2003; Stemmler et al, 2003; Talar-Wojnarowska et al, 2003; Ziske
et al, 2003; Gupta et al, 2004). One was based on five observational
studies with varied inclusion criteria, inconsistent results and no
prospective verification (Terwee et al, 2000). The largest series
(2380 patients) identified factors based on univariate analyses and
data containing a large proportion (57%) of censored patients
(Storniolo et al, 1999).
An important issue in prognostic factor studies is the nature of
the relationship between the factor and survival (functional form).
Continuous variables are often simplified at analysis by assuming a
linear relationship with log-hazard or by introducing a step
function through categorisation (frequently dichotomisation). If
the linearity assumption is not correct, the final prognostic model
could be misspecified. Misspecification of the functional form may
lead to inappropriate conclusions but has not been previously
investigated in pancreatic cancer studies. Many researchers avoid
this problem by dichotomising, with a consequent loss of power.
There is also the risk of important bias when the choice of cutoff is
data-driven and the use of different cutoff points across multiple
studies hinders direct comparisons.
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baseline prognostic factors for survival in advanced pancreatic
cancer using prospective data from two randomised controlled
trials and a total of 653 patients (Bramhall et al, 2001, 2002). The
study investigated clinical, histological, biochemical and demo-
graphic variables. A multivariable approach was used accounting
for the functional form of the relationship between continuous
factors and survival. Models were developed either on the basis of
standard assumptions of log linear or step functional relationships
with survival, or a novel approach based on nonlinear relation-
ships, using more complex fractional polynomial (FP) transforma-
tions: a flexible, parametric method for modelling nonlinear
Table 1 Literature review
Type (number)
of studies
Number of patients
per study Prognostic factors reported (frequency of reporting)
Uo rM V
analysis
Randomised controlled 207–322 Surgical Metastases (3) 4 MV
trial (n¼4)
3–6 Tumour location (1)
Clinical Performance status (3)
Treatment (1)
Laboratory Alkaline phosphatase (1)
Consecutive series 782–2380 Surgical Metastases (1) 2 MV
4500 patients (n¼3)
7–9 Stage of disease (1) 1 U
Operation (1)
Clinical Performance status (1)
Diabetes (1)
Pain (1)
Appetite/weight (1)
Jaundice (1)
Treatment (1)
Laboratory Albumin (1)
Demographic Age (1)
Specialist centre (1)
Consecutive series 100–500 102–450 Surgical Metastases (4) 13 MV
patients (n¼14)
10–23 Stage of disease (2) 1 U
Tumour location (1)
Operation (2)
Tumour size (1)
Duodenal invasion (1)
Peridissemination (1)
Ascites (1)
Clinical Performance status (2)
Diabetes (1)
Pain (1)
Appetite/weight (3)
Symptom onset (1)
Treatment (2)
Laboratory CA242 (2)
CA19-9 (2)
Leukocytes (1)
Gamma GT (1)
Albumin (1)
LDH (1)
CRP (3)
Iron (1)
Demographic Age (1)
Consecutive series 28–95 Surgical Metastases (1) 8 MV
o100 patients (n¼15)
24–38 Stage of disease (1) 7 U
Grade of disease (1)
Nodal status (1)
Operation (1)
Tumour size (2)
Fibrosis (1)
Clinical Performance status Inflammation (4)
Appetite/weight (1)
Treatment (1)
Laboratory CA19-9 (1)
VEGF (7)
CEA (1)
Phase angle BIA (1)
SCA (1)
(1)
MV¼multivariate; U¼univariate.
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srelationships (Royston and Altman, 1994; Altman and Lyman,
1998).
PATIENTS AND METHODS
Data
Two international phase III British Biotech studies (BB128,
Bramhall et al, 2001; BB193, Bramhall et al, 2002) randomised
414 and 239 patients with advanced pancreatic cancer, respec-
tively: BB128 randomised patients between marimistat and
gemcitabine; BB193 randomised patients between marimistat with
gemcitabine and gemcitabine alone. The studies had similar
eligibility criteria: histologically or cytologically unresectable
pancreatic cancer, within 8 weeks of diagnosis or disease
recurrence and Karnofsky performance status of X50% (BB128)
or X60% (BB193). Previous therapy for metastatic or locally
advanced disease was an exclusion criterion. The primary outcome
measure in both studies was survival time calculated from the date
of randomisation to the date of death from any cause.
Randomisation was stratified by cancer stage (stage I/II, III or
IV), Karnofsky performance status (50–70%, 80–100%), sex and
study centre. The first stage of data reduction was considering only
factors that were clinically relevant and available within an NHS
outpatient clinic. Eighteen baseline clinical, histological, bio-
chemical and demographic variables (including trial and
randomised treatment group) were considered appropriate for
analysis as possible prognostic factors (Table 2).
Statistical analysis
We followed a strategy aimed at maximising model performance
and avoiding poorly fitted and overfitted regression models
in the development (Harrell et al, 1996) and reporting (McShane
et al, 2005) of multivariable prognostic models. Initial analysis
was based on standard methodology comparing Kaplan–Meier
survival estimates using the log-rank test and estimating univariate
hazard ratios for levels of each factor. The hazard of death
was assessed in the multivariable setting using Cox proportional
hazards regression modelling with variable reduction by
backward elimination. The proportional hazards assumption
was investigated for each covariate using log cumulative
hazard (Collett, 1994) and martingale residual plots, and
incorporating a time-dependent covariate (X¼factor(LN
(survival) LN (mean survival))) and did not indicate any
significant violation.
Ten of the 18 possible prognostic factors were collected as
continuous measurements. Continuous data were investigated by
assessing three different assumptions of the underlying relation-
ship between survival and predictor, they are: (a) a linear
relationship between the predictor and log hazard, (b) a step
functional relationship using dichotomised covariates (laboratory
measures based on central laboratory reference ranges) and (c) a
nonlinear relationships based on either a simple log or more
complex nonlinear FP transformation (Royston and Altman, 1994).
For the third model, the functional form of each variable was
assessed univariately comparing the Akaike’s Information Criter-
ion (AIC) (Collett, 1994) of a model based on the simple log
transformation with the AIC of a model based on the best fitting
FP transformation. First- and second-degree FP transformations
(Meier-Hirmer et al, 2003) were considered using a selection level
of 0.05 for input of variables based on power values of the
polynomial ranging ( 2,  1,  0.5, 0 (log), 0.5, 1, 2, 3). The best FP
for each predictor was selected if it resulted in a significantly better
fit (significantly smaller AIC) than the log transformation. The
most appropriate (log or FP) transformation, if any, was applied to
each variable and all variables were considered multivariately
using Cox proportional hazards regression based on a backward
selection method using a nominal significance level of 0.05 for
elimination and including trial, sex, cancer stage (stratification
factors at randomisation) and randomised treatment in each
model.
The majority of variables had p5% missing values (Table 2).
Tumour stage, CA19-9 and WBC had 5–10% missing values, and
lymph node status was missing for 24% of patients. Metastases or
lymph node status was considered in the analysis as dummy
variables using ‘negative’ as a reference level. Primary analysis was
based on complete cases and a secondary analysis used multiple
imputation to investigate the possible influence of variables with
larger amounts of missing data (Rubin, 1987; Schafer, 1997) and
provided valid inferential alternative results.
Model fit was assessed comparing AIC statistics, deviance
residuals and Kaplan–Meier survival statistics for four predictive
groups. The four predictive groups were based on quartiles of
linear predictor scores, assessed comparing median survival
estimates and hazard ratios. The bootstrap resampling approach
described by Harrell et al (1996) was applied to assess the extent of
overfitting in the final model, using 200 bootstrap resamples. This
approach repeats the model selection methods used in the original
model development in a series of bootstrapped resamples, freezing
the derived model and applying to the original sample. Model
optimism (overfitting) is described by the difference in the rank
correlation coefficient relating predicted and observed survival
times between the model derived in the bootstrap resample and
that from the frozen model applied to the original sample averaged
over 200 resamples. This provides an honest estimate of internal
validity penalised for overfitting (Harrell et al, 1996).
Analyses were carried out using SAS and R using a two-sided
significance level of 0.05 throughout.
RESULTS
Patient characteristics
A total of 653 patients were randomised. The eighteen clinically
appropriate factors for analysis are presented in Table 2 and
appear balanced across the two studies. On average, patients in the
two trials were randomised 20 and 15 days after diagnosis and
started treatment the day following randomisation. The average
age of patients was 63 years (range 29–89), 368 (56%) were male,
439 (68%) had cancer stage IV disease, 436 (67%) presenting with
metastases and 251 (39%) had lymph node involvement.
Survival
The majority of patients (612, 94%) had died by the time of
analysis with a median follow-up time of 21 months for the 41
patients still alive (Table 2, Figure 1). The median survival estimate
for the group is 4.7 months (95% CI: 4.2, 5.1) with 12-month
survival estimate of 17% (Figure 1). Hazard functions estimated for
1-monthly time intervals to 18 months from trial entry were
similar for both trials and reasonably constant over time. No
significant survival benefit for marimastat was identified in the
BB128 trial (P¼0.19) when compared with gemcitabine (Bramhall
et al, 2001). Similarly, no significant survival benefit was seen for a
combination of gemcitabine and marimistat when compared with
gemcitabine alone in the BB193 trial (P¼0.95) (Bramhall et al,
2002).
Univariate analyses
Log-rank analyses (Table 3) indicated that potentially important
factors were age (split at median, P¼0.036), nodal status
(P¼0.035), cancer stage (I/II vs III/IV), metastases (both
Po0.001) and laboratory measures (split as normal/abnormal
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sTable 2 Patient characteristics by trial
Variable BB128
39 N¼414 (63%) BB193
40 N¼239 (37%) Total N¼653 (100%)
Demographics
Age at entry (years)
a
Median 63 62 63
Range 29–89 32–85 29–89
Ethnic race
White 364 (88%) 226 (95%) 590 (90%)
Black 27 (6%) 8 (3%) 35 (6%)
Oriental 7 (2%) 0 7 (1%)
Other 15 (4%) 5 (2%) 20 (3%)
Missing 1 0 1
Sex
Male 228 (55%) 140 (59%) 368 (56%)
Female 186 (45%) 99 (41%) 285 (44%)
Treatment
Gemcitabine 103 (25%) 119 (50%) 222 (34%)
Marimistat 311 (75%) 120 (50%) 431 (66%)
Tumour information
Cancer stage
I 19 (4%) 13 (5%) 32 (5%)
II 45 (11%) 27 (11%) 72 (11%)
III 76 (19%) 28 (12%) 104 (16%)
IV 268 (66%) 171 (72%) 439 (68%)
Missing 6 0 6
Distant metastases
M0 129 (31%) 65 (27%) 194 (30%)
M1 265 (64%) 171 (72%) 436 (67%)
Missing 20 (5%) 3 (1%) 23 (3%)
Regional lymph nodes
N0 153 (37%) 90 (38%) 243 (37%)
N1 164 (40%) 87 (36%) 251 (39%)
Missing 97 (23%) 62 (26%) 159 (24%)
Primary tumour T stage
T0 5 (1%) 3 (1.5%) 8 (1.5%)
T1 114 (30%) 44 (20%) 158 (26%)
T2 90 (24%) 54 (25%) 144 (24%)
T3 167 (44%) 113 (53%) 280 (47%)
T4 6 (1%) 1 (0.5%) 7 (1.5%)
Missing 32 24 56
Serum chemistry and haematology
Laboratory variables Median (range), missing Median (range), missing Median (range), missing
AST (SGOT)
a 24 (6–365), 17 26 (9–538), 12 25 (6–538), 29
Total bilirubin
a 13.7 (3.4–277.0), 16 13.7 (3.0–135.1), 8 13.7 (3.0–277.0), 24
Alkaline phosphatase
a 136 (36–1660), 16 157 (35–2064), 8 140 (35–2064), 24
Albumin
a 38 (22–47), 17 38 (24–47), 8 38 (22–47), 25
LDH
a 163 (77–1074), 21 169 (29–1495), 11 164 (29–1495), 32
BUN
a 9.2 (2.9–34.3), 17 9.3 (4.3–27.9), 16 9.3 (2.9–34.3), 33
CA19/9
a 686 (5–1000000), 17 800 (8–1000000), 30 710 (5–1000000), 47
Haemoglobin
a 12.5 (5.5–16.1), 28 12.4 (8.3–19.1), 13 12.4 (5.5–19.1), 41
WBC
a 7.6 (2.3–31.6), 28 8.3 (2.4–23.7), 13 7.9 (2.3–31.6), 41
Outcome
Event indicator
Alive 22 (5%) 19 (8%) 41 (6%)
Dead 392 (95%) 220 (92%) 612 (94%)
Follow-up of alive (months)
a
Median 20.1 19.4 20.7
Range 0.9–24.6 1.9–23.3 0.9–24.6
aContinuous measurements.
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practise) as AST, alkaline phosphatase, albumin, LDH, WBC (all
Po0.001), bilirubin (P¼0.002), CA19-9 (P¼0.005) and haemo-
globin (P¼0.009). Trial, treatment (gemcitabine vs marimistat),
race (white vs not-white), sex, tumour stage (T0, 1, 2 vs T3, 4) and
BUN were not significantly related to survival.
Multivariate analyses
Three Cox proportional hazards regression models were developed
(Table 4) using 556 patients (520 deaths) with complete data
(excluding patients with missing data) based on the assumption of
(a) a linear relationship between continuous covariates and log
hazard, (b) a step functional dichotomisation of continuous
covariates and (c) a nonlinear transformation of continuous
covariates. All three models included trial, sex, cancer stage
(stratification factors at randomisation) and randomised treatment
group.
The ‘linear’ model (Table 4, Model 1) identified five highly
significant prognostic factors, namely albumin, alkaline phospha-
tase, LDH, WBC and metastases. The ‘categorical’ model (Table 4,
Model 2) identified six highly significant prognostic factors,
namely LDH, albumin, metastases, WBC, CA19-9 and bilirubin.
Univariate analysis of the 10 continuous variables identified that
nonlinear transformations were appropriate for 3 variables in their
relationship with survival: bilirubin and LDH both as log
transformations and CA19-9 as a second-degree FP transformation
(CA19-9
0.5þ(CA19-9
0.5 log(CA19-9))). The seven remaining
continuous covariates were analysed assuming a linear relation-
ship with log hazard, as in Model 1. The ‘transformed’ model
(Table 4, Model 3) identified eight prognostic factors. Five factors
were highly significant with Po0.01, namely albumin, CA19-9,
LDH, alkaline phosphatase and WBC with AST, BUN and
metastases being more borderline in the model (P¼0.023, 0.026
and 0.047, respectively).
Nonlinear transformations were appropriate for two variables,
LDH and CA19-9, and the estimated log hazard ratio functions are
shown graphically in Figures 2 and 3. The second-degree FP
function for CA19-9 estimates increasing risk up to an approx-
imate CA19-9 value of 14000 and then decreases with increasing
CA19-9. The log function for LDH estimates increasing risk for
increasing values of LDH.
Model comparison
In all three models, albumin, LDH and WBC were highly
statistically significant and influential prognostic factors. Meta-
stases were also an important variable but its parameter estimate
and overall significance were reduced in the ‘transformed’ model
when continuous covariates were included in a more appropriate
format. In both the ‘linear’ and ‘transformed’ models, alkaline
phosphatase was also a highly significant and influential prog-
nostic factor. CA19-9 was also a highly significant and influential
prognostic factor in both the ‘categorical’ and ‘transformed’
models. This variation is largely explained by the nonlinear
relation of CA19-9 to survival (Figure 2), which could explain why
it was considered important when dichotomised but not when
included as linear. When considered as a transformed second-
degree FP, its significance was much greater. Bilirubin was selected
as a highly significant factor in the ‘categorical’ model but was not
included in either the ‘linear’ or ‘transformed’ models. AST and
BUN were only selected as prognostic in the ‘transformed’ model.
Model performance
The AIC statistic was smallest for the ‘transformed’ model (Table 4,
Model 3), indicating a better fit to the data. Deviance residuals for
this model were plotted against the linear predictor and were
randomly scattered centred around a residual value of zero
ranging between  3.86 and 3.33, which suggests the data have not
been mis-modelled.
Patients were split into four groups based on quartiles of the
distribution of linear predictor scores from the ‘transformed’
model. Kaplan–Meier survival estimates (Figure 4) show four
distinct predictive groups with descending median survival
estimates of 9.1 (95% CI: 7.4, 10.9), 7.0 (95% CI: 5.9, 8.3), 4.0
(95% CI: 3.4, 4.9) and 2.0 (95% CI: 1.6, 2.4) months. The hazard
ratios for groups 2, 3 and 4 using predictive group 1 as the baseline
were 1.35 (95% CI: 1.09, 1.66), 2.08 (95% CI: 1.64, 2.64) and 4.21
(95% CI: 3.11, 5.68), respectively.
When assessing model validity, the R
2 measure of model fit was
estimated as 0.30. The bootstrap resampled estimate of R
2 of 0.26
described model optimism (overfitting) under 5% and gives an
improved estimate of model accuracy.
Multiple imputation allowed all 653 patients to be included in
the modelling process and confirmed all the variables included in
the ‘transformed’ model with increased significance for metastases
(P¼0.001), and the model also included nodal status (P¼0.016)
that had been excluded from all models prior to imputation,
suggesting a strong link with other variables already in the model.
DISCUSSION
Large, prospective, phase III randomised controlled trials aim to
provide robust statistical evidence for new treatment combina-
tions. Stratification is important to control for known important
variability in the data. Generally, patients with pancreatic cancer
are not clinically separated into prognostic groups, with the
exception of surgical status, before consideration for treatment.
This study investigated potentially important baseline prognostic
factors for survival as possible stratification variables for
randomisation and analysis. Data from 653 patients included in
two international randomised controlled trials in advanced
pancreatic cancer (Bramhall et al, 2001, 2002) were analysed
investigating multiple clinical, histological, biochemical and
demographic variables in the form of both binary and continuous
measurements. Valid statistical analyses are necessary to make
best use of the data and optimise clinical results. As such, a
multivariable approach was used to account for the functional
form of the relationship between continuous prognostic variable
factors and survival. Misspecification of functional form may lead
to inappropriate conclusions but has not been previously
investigated in pancreatic cancer studies. Continuous variables
are often simplified by assuming a linear relationship between
predictor and log hazard, that is the log risk increases or decreases
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sTable 3 Univariate log-rank analyses
Patients Deaths 12-month survival (%) Median survival (95% CI) v
2
LR,p( v
2
W, p) HR (95% CI)
Overall survival 653 612 17 4.7 (4.2, 5.1) — —
Trial
BB128 414 392 17 4.2 (3.6, 4.8) 2.28, P¼0.13 1.0
BB193 239 220 18 5.4 (4.8, 6.0) 0.88 (0.75, 1.04)
Demographics
Age group (years)
o¼63 343 320 21 5.1 (4.3, 5.8) 4.42, P¼0.036 1.0
463 310 292 13 4.3 (3.5, 4.9) (7.55, P¼0.006) 1.18 (1.01, 1.39)
Ethnic group
White 590 554 18 4.6 (4.1, 5.1) 0.20, P¼0.65 1.0
Other 62 57 12 5.2 (3.5, 6.0) 1.06 (0.80, 1.41)
Sex
Female 285 267 18 4.9 (4.2, 5.8) 0.73, P¼0.39 1.0
Male 368 345 17 4.5 (3.9, 5.1) 1.07 (0.91, 1.26)
Treatment
Gemcitabine 222 204 18 5.5 (4.7, 5.9) 2.79, P¼0.095 1.0
Marimistat 431 408 17 4.2 (3.5, 4.9) 1.15 (0.98, 1.36)
Tumour information
Cancer stage
Early (I/II) 104 92 26 6.8 (5.7, 8.2) 14.72, Po0.001 1.0
Late (III/IV) 543 514 16 4.1 (3.5, 4.7) 1.53 (1.26, 1.86)
Metastases
M0 194 176 30 6.8 (5.9, 8.4) 35.47, Po0.001 1.0
M1 436 414 12 3.5 (3.2, 4.0) 1.69 (1.43, 1.99)
Missing 23 22 17 5.5 (4.9, 7.5) 1.35 (0.88, 2.09)
Lymph nodes
N0 243 226 20 5.5 (4.8, 6.0) 6.73, P¼0.035 1.0
N1 251 240 18 4.5 (3.5, 5.4) 1.19 (1.00, 1.43)
Missing 159 146 11 3.8 (3.2, 4.9) 1.29 (1.04, 1.59)
Tumour stage
Early (0/1/2) 310 291 16 4.3 (3.7, 4.9) 1.63, P¼0.44 1.0
Late (3/4) 287 268 18 4.9 (4.2, 5.8) 0.91 (0.77, 1.08)
Missing 56 53 18 5.8 (3.5, 7.9) 0.87 (0.66, 1.16)
Serum chemistry and haematology
AST (SGOT)
Normal 538 499 19 5.1 (4.6, 5.7) 14.17, Po0.001 1.0
Abnormal 86 84 12 2.8 (2.2, 3.9) (5.99, P¼0.014) 1.55 (1.18, 2.04)
Total bilirubin
Normal 464 429 20 5.1 (4.7, 5.7) 9.32, P¼0.002 1.0
Abnormal 165 159 11 3.8 (3.3, 4.4) (6.27, P¼0.012) 1.32 (1.09, 1.61)
Alkaline phosphatase
Normal 442 411 20 5.5 (5.0, 6.1) 20.20, Po0.001 1.0
Abnormal 187 177 13 3.1 (2.6, 3.5) (56.05, Po0.001) 1.49 (1.23, 1.81)
Albumin
Normal 583 544 19 5.1 (4.6, 5.6) 31.37, Po0.001 1.0
Abnormal 45 43 7 1.5 (1.0, 2.7) (74.34, Po0.001) 2.36 (1.49, 3.72)
LDH
Normal 543 505 20 5.2 (4.8, 5.8) 37.05, Po0.001 1.0
Abnormal 78 75 5 2.1 (1.5, 2.8) (36.16, Po0.001) 2.08 (1.50, 2.88)
BUN
Normal 407 382 20 5.1 (4.3, 5.7) 3.43, P¼0.064 1.0
Abnormal 213 199 13 4.4 (3.5, 5.1) (5.28, P¼0.022) 1.17 (0.98, 1.40)
CA19/9
Normal 98 86 28 6.3 (4.8, 8.0) 7.74, P¼0.005 1.0
Abnormal 508 481 16 4.6 (4.0, 5.1) (4.84, P¼0.028) 1.38 (1.12, 1.70)
Haemoglobin
Normal 79 77 8 3.7 (3.3, 5.1) 6.88, P¼0.009 1.0
Abnormal 533 495 20 4.9 (4.4, 5.6) (10.64, P¼0.001) 0.73 (0.55, 0.95)
WBC
Normal 483 446 21 5.5 (4.9, 5.9) 34.36, Po0.001 1.0
Abnormal 129 126 8 2.9 (2.4, 4.0) (46.52, Po0.001) 1.78 (1.40, 2.26)
HR¼hazard ratio; LR¼log-rank statistic; W¼Wald w
2 statistic.
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sTable 4 Cox proportional hazards regression models, n¼556 patients, 520 deaths
Variable v
2 P-value HR (95% CI)
(a) Model 1 – ‘Linear’ covariates
Full model
AIC¼5558.4
Stratification factors Trial 7.3 0.007 0.76 (0.63, 0.93)
Cancer stage
a 0.0001 0.99 1.00 (0.69, 1.44)
Sex 3.8 0.050 0.82 (0.68, 1.00)
TRT 2.6 0.11 1.17 (0.97, 1.42)
Independent factors Age 3.0 0.081 1.01 (1.00, 1.02)
Albumin 22.9 o0.001 0.94 (0.92, 0.96)
Alkaline phosphatase 24.3 o0.001 1.00 (1.00, 1.00)
AST 5.3 0.022 1.00 (0.99, 1.00)
Bilirubin 0.7 0.40 1.00 (1.00, 1.01)
BUN 2.3 0.13 1.02 (0.99, 1.05)
CA19/9 0.9 0.34 1.00 (1.00, 1.00)
Ethnic 0.0009 0.98 1.01 (0.74, 1.36)
Haemoglobin 0.01 0.91 1.00 (0.94, 1.08)
LDH 19.3 o0.001 1.00 (1.00, 1.00)
METS
b 8.5 0.004 1.50 (1.14, 1.96)
Nodes
b 0.4 0.51 1.08 (0.86, 1.37)
Tumour stage
b 0.03 0.86 1.02 (0.84, 1.23)
WBC 10.2 0.001 1.04 (1.02, 1.07)
Final model
AIC¼5557.1
Stratification factors Trial 8.1 0.005 0.76 (0.63, 0.92)
Cancer stage
a 0.008 0.93 1.01 (0.74, 1.38)
Sex 3.8 0.051 0.84 (0.70, 1.00)
TRT 3.2 0.073 1.19 (0.98, 1.44)
Independent factors Albumin 41.0 o0.001 0.94 (0.92, 0.96)
LDH 13.3 o0.001 1.00 (1.00, 1.00)
METS
b 10.5 0.001 1.50 (1.17, 1.92)
WBC 11.7 o0.001 1.04 (1.02, 1.07)
Alkaline phosphatase 21.1 o0.001 1.00 (1.00, 1.00)
(b) Model 2 – ‘Categorical’ covariates
Full model
AIC¼5582.3
Stratification factors Trial 5.8 0.016 0.79 (0.65, 0.96)
Cancer stage
a 0.0001 0.99 1.00 (0.70, 1.44)
Sex 2.1 0.14 0.87 (0.72, 1.05)
TRT 3.3 0.07 1.19 (0.99, 1.44)
Independent factors Age 2.2 0.13 1.15 (0.96, 1.39)
Albumin 17.6 o0.001 2.08 (1.48, 2.93)
Alkaline phosphatase 0.3 0.57 1.07 (0.85, 1.34)
AST 1.5 0.22 1.20 (0.90, 1.59)
Bilirubin 5.0 0.025 1.28 (1.03, 1.58)
BUN 1.9 0.17 1.14 (0.94, 1.39)
CA19/9 7.8 0.005 1.43 (1.11, 1.85)
Ethnic 0.5 0.48 0.89 (0.66, 1.22)
Haemoglobin 2.2 0.14 0.82 (0.62, 1.07)
LDH 22.8 o0.001 2.07 (1.54, 2.79)
METS
b 13.3 o0.001 1.64 (1.26, 2.14)
Nodes
b 2.3 0.13 1.20 (0.95, 1.51)
T stage
b 0.06 0.80 0.98 (0.81, 1.18)
WBC 9.2 0.002 1.42 (1.13, 1.78)
Final model
AIC¼5583.2
Stratification factors Trial 7.0 0.008 0.77 (0.64, 0.94)
Cancer stage
a 0.9 0.36 1.16 (0.85, 1.58)
Sex 1.8 0.18 0.89 (0.74, 1.06)
TRT 3.4 0.065 1.19 (0.99, 1.44)
Independent factors Albumin 24.2 o0.001 2.30 (1.65, 3.21)
LDH 25.1 o0.001 2.05 (1.55, 2.72)
METS
b 11.9 o0.001 1.54 (1.21, 1.97)
WBC 10.3 0.001 1.44 (1.15, 1.79)
Bilirubin 8.4 0.004 1.34 (1.10, 1.64)
CA199 9.4 0.002 1.48 (1.15, 1.89)
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slinearly as the value of the factor increases, which may not be
appropriate. Dichotomisation of continuous data is common but is
problematic and unnecessary. As the variability in outcome within
groups is ignored by categorisation, the variability between groups
may be significantly underestimated as patients close to the cut
point are analysed as being very different rather than being very
Table 4 (Continued)
Variable v
2 P-value HR (95% CI)
(c) Model 3–‘Transformed’ covariates
Full model
AIC¼5509.6
Stratification factors Trial 12.5 o0.001 0.70 (0.57, 0.85)
Cancer stage
a 0.2 0.68 0.93 (0.64, 1.33)
Sex 4.3 0.038 0.82 (0.67, 0.99)
TRT 3.0 0.082 1.19 (0.98, 1.44)
Independent factors
Linear Age 2.3 0.13 1.01 (1.00, 1.02)
Linear Albumin 20.8 o0.001 0.94 (0.92, 0.97)
Linear Alkaline phosphatase 11.3 o0.001 1.00 (1.00, 1.00)
Linear AST 7.5 0.0062 1.00 (0.99, 1.00)
1st degree FP Log (bilirubin) 3.0 0.083 1.16 (0.98, 1.37)
Linear BUN 3.2 0.075 1.02 (1.00, 1.05)
2nd degree FP CA199
0.5 36.3 o0.001 1.03 (1.02, 1.03)
2nd degree FP CA199
0.5 log(CA199) 30.9 o0.001 1.00 (1.00, 1.00)
Categorical Ethnic 0.1 0.74 0.95 (0.70, 1.29)
Linear Haemoglobin 0.3 0.61 0.98 (0.92, 1.05)
1st degree FP Log (LDH) 12.3 o0.001 1.72 (1.27, 2.32)
Categorical METS
b 6.1 0.014 1.41 (1.07, 1.85)
Categorical Nodes
b 1.4 0.24 1.15 (0.91, 1.46)
Categorical Tumour stage
b 0.3 0.60 1.05 (0.87, 1.28)
Linear WBC 10.5 0.0012 1.05 (1.02, 1.07)
Final model
AIC¼5510.2
Stratification factors Trial 15.1 o0.001 0.68 (0.56, 0.83)
Cancer stage
a 0.001 0.97 1.0 (0.73, 1.36)
Sex 3.5 0.061 0.84 (0.70, 1.01)
TRT 3.16 0.075 1.19 (0.98, 1.44)
Independent factors
Linear Albumin 41.4 o0.001 0.94 (0.92, 0.95)
1st degree FP Log (LDH) 12.8 o0.001 1.70 (1.27, 2.27)
Categorical METS
b 4.0 0.047 1.29 (1.00, 1.66)
Linear WBC 10.0 0.002 1.04 (1.02, 1.07)
Linear Alkaline phosphatase 14.6 o0.001 1.00 (1.00, 1.00)
Linear AST 5.2 0.023 1.00 (0.99, 1.00)
Linear BUN 5.0 0.026 1.03 (1.00, 1.06)
2nd degree FP CA199
0.5 33.3 o0.001 1.02 (1.02, 1.03)
2nd degree FP CA199
0.5 log(CA199) 28.4 o0.001 1.00 (1.00, 1.00)
FP¼fractional polynomial; HR¼hazard ratio.
aStage (I/II vs III/IV).
bMetastases (negative vs positive), Nodes (negative vs positive), Tumour stage (I/II vs III/IV): missing data
included in analysis as a separate ‘dummy’ variable using lower level as the reference level.
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Figure 2 Estimated functional form for CA19-9. Dots indicate actual
data values.
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Figure 3 Estimated functional form for LDH. Dots indicate actual data
values.
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ssimilar, resulting in a serious reduction of statistical power to detect
relationships between predictors and outcome, residual confounding
and serious bias (Altman and Royston, 2006; Royston et al, 2006a).
Regression using FPs of continuous covariates has been used in data
from breast cancer (Sauerbrei et al, 1999) and metastatic renal
carcinoma (Royston et al, 2006b) trials. Our study supported these in
showing that this approach allowed important additional prognostic
information to be extracted with less sophisticated approaches
missed. FPs provide a flexible, parametric approach for modelling
nonlinear relationships, making full use of the information available
within each variable and as such can provide a clearer insight into the
nature of the underlying relationship (Royston and Altman, 1994;
Altman and Lyman, 1998).
Pancreatic ductal adenocarcinoma is the fifth most common
cause of death from cancer in the Western world (Bramhall et al,
1995; Parkin et al, 2001; Jemal et al, 2003). It is particularly difficult
to treat because of its remote location, late presentation and
resistance to conventional chemotherapy. Long-term survival
remains poor with a 5-year survival rate between 0.4 and 4%
(Bramhall et al, 1995; Jemal et al, 2003). Resection is associated
with improved survival but this is only possible in approximately
10% of patients (Sener et al, 1999; Alexakis et al, 2004). Although
significant improvements in surgical outcome have been obtained
with increasing specialisation (Neoptolemos et al, 1997; Birkmeyer
et al, 1999), further benefits are anticipated by identifying high-
risk groups. A validated prognostic index would identify
subgroups of patients for specific treatments and predict survival,
but there is no tool in routine use. Also, many possible prognostic
factors have been identified in advanced pancreatic cancer
(Table 1), most derived from retrospective studies based on small
numbers of patients resulting in analyses that may be under-
powered. A total of 34 possible factors were identified from 36
studies (4 randomised controlled trials; Johnson et al, 2001; Berlin
et al, 2002; Ducreux et al, 2002; Maisey et al, 2002) and 32
consecutive series (Friedman and van den Eeden, 1993; Yasue et al,
1994; Falconer et al, 1995; Lundin et al, 1995; Ishii et al, 1996;
Rothenberg et al, 1996; Shibamoto et al, 1996; Cubiella et al, 1999;
Storniolo et al, 1999; Halm et al, 2000; Terwee et al, 2000; Trigui
et al, 2000; Ueno et al, 2000; Ikeda et al, 2001; Ridwelski et al, 2001;
Tas et al, 2001; Tsuruta et al, 2001; Saad et al, 2002; Bachmann
et al, 2003; Engelken et al, 2003; Fujino et al, 2003; Karayiannakis
et al, 2003; Micke et al, 2003; Ohigashi et al, 2003; Paillaud et al,
2003; Stemmler et al, 2003; Talar-Wojnarowska et al, 2003; Ziske
et al, 2003; Gupta et al, 2004; Kuhlmann et al, 2004; Watanabe et al,
2004; Ni et al, 2005) of which 15 had o100 patients (Yasue et al,
1994; Ishii et al, 1996; Rothenberg et al, 1996; Halm et al, 2000;
Ikeda et al, 2001; Tsuruta et al, 2001; Saad et al, 2002;
Karayiannakis et al, 2003; Micke et al, 2003; Ohigashi et al, 2003;
Paillaud et al, 2003; Stemmler et al, 2003; Talar-Wojnarowska et al,
2003; Ziske et al, 2003; Gupta et al, 2004), including demographic,
clinical (including, performance status, weight loss and treatment),
surgical (including, palliative procedures, site and stage of disease)
and laboratory (including, CA19-9, LDH, alkaline phosphatase and
albumin). Further concerns include the inadequate use of statistical
methods, model comparison when different factors are being
investigated and the differing format of factors across studies.
We developed three prognostic models, two based on standard
assumptions of log linear or step functional relationships with
survival and a novel approach based on nonlinear relationships
using more complex FP transformations. The model based on
transformed covariates (Table 4, Model 3) was the best-fitting
model, better utilising the information within nonlinear covariates.
This model confirmed five previously reported prognostic factors,
namely albumin, CA19-9, alkaline phosphatase, LDH and metas-
tases; and also identified three additional possible prognostic
factors not previously reported: WBC, AST and BUN. Nonlinear
transformations were appropriate for two variables indicating
strong nonlinear effects on survival: CA19-9 as a second-degree FP
and LDH under a log transformation. Importantly, the effect of
CA19-9 was not apparent in the ‘linear’ model, the effect of alkaline
phosphatase was not apparent in the ‘categorical’ model and the
effects of AST and BUN were not apparent in either the ‘linear’ or
‘categorical’ models, indicating how the significant effect of these
variables may go unrecognised due to simplistic assumptions
made in statistical modelling.
Shrinkage represents the degree to which a plot of predicted and
observed values is flattened from the 451 line attributable to
overfitting. Overfitting leads to inflated estimates of model fit and
is a potentially important source of bias in prognostic models.
Overfitting may be minimised through sensible model selection,
which for survival models implies avoiding attempting to fit
models with more than 1 candidate variable (degree of freedom)
for each 10 events of interest (e.g., death) included in the analysis.
The degree to which overfitting is present in the fitted model may
be estimated either directly through validation in an external data
set or through a bootstrap process. In practise, it is rare for an
external data set to be available, and if data are scarce, it becomes
attractive to use all available data to derive the prognostic model.
Thus, bootstrap resampling approaches may become the model
validation methods of choice. In our model, bootstrap resampling
methods (Harrell et al, 1996) suggested minimal optimism. As
shrinking estimators will not increase the real discrimination of
the model, and the degree of overfitting estimated for the model is
minimal, rescaling the model estimates appears neither helpful nor
necessary.
A model based on multiple imputation methods (Rubin, 1987;
Schafer, 1997) to control for missing covariate data selected an
additional variable nodal status as prognostic (P¼0.016), which
had been excluded from all models prior to imputation. The true
importance of this variable requires further investigation, suggest-
ing a strong link with other variables already in the model.
All prognostic models ideally require external validation
to determine the generality across different data sets, and our
results may be seen as provisional until replicated on independent
data. Performance status and tumour size at randomisation are
well-documented factors (Table 1) but unfortunately were not
available in this data set and should be included in any external
validation.
This research was based on data from two large, phase III
randomised controlled trials representative of patients with
advanced pancreatic cancer with a high event rate, long follow-
up and an overall 1 year survival rate of 17% (Bramhall et al, 2001,
2002). Analyses were based on a multivariable approach and
utilised the information contained within continuous variables
appropriately. The functional form of the relationship between
continuous covariates and survival should always be assessed
when investigating potential prognostic value. Models were based
on information readily available in clinic and once validated
should have the ability to aid decision-making by identifying
patients with borderline disease for surgery and patients for
inclusion into clinical trials or off-study treatment, especially since
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sa greater number of palliative and more toxic treatments are
becoming available and being trialed in this disease.
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